Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936065 | 0.96 | ITGB3 (0.51) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6935801 | 0.96 | ITGB3 (0.52) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6539432 | 0.96 | ITGB3 (0.52) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7501275 | 0.94 | ITGB3 (0.49) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7502464 | 0.90 | ITGB3 (0.49) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7496206 | 0.90 | ITGB3 (0.51) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7494017 | 0.89 | ITGB3 (0.51) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6540119 | 0.87 | ITGB3 (0.50) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7498526 | 0.84 | ITGB3 (0.49) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7498844 | 0.84 | KDM4E (0.50) | ITGB3ITGA2BNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| US-6538007-B1 | Hydrates and method of antogonizing glycoprotein IIb/IIIa activity using these compounds is also disclosed. antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114488-A1 | New processes for producing beta-alanine derivatives | BCAT1, BCAT2, AGXT | ITGB3 3266/4885ITGA2B 3019/4885NPC1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.